Skip to main content

Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection

Hikma pharmaceuticals plc

ISIN: GB00B0LCW083 , WKN: A0HG69

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment\'s principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment\'s principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment\'s principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Hikma Pharmaceuticals downgraded to Hold from Buy at Jefferies

2023-11-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Hikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gains

2023-11-06
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Hikma price target lowered to 2,000 GBp from 2,175 GBp at Barclays

2023-11-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

The one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past week

2023-10-05
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Stock Market Today: Dow Drops, Bond Yields Climb

2023-10-03
Stocks fell broadly as Treasury yields climbed further and investors bet that the economy’s strength would mean higher borrowing costs for longer.

Health Care Roundup: Market Talk

2023-10-03
0814 GMT – The FTSE 100 trades steady at 7511.33 in early trade while European stock fall as concerns about rising bond yields return to weigh on sentiment and positive news over the weekend on the U.S. avoiding a government shutdown fades. The FTSE 100 outperforms European indexes, however, with the Stoxx Europe 600 falling 0.2%. Pharma stocks are among the main FTSE 100 gainers, with Hikma Pharmaceuticals up 1.2%, GSK rising 0.5% and AstraZeneca edging up 0.2%.

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

2023-10-03
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO® (naloxone HCl) nasal spray 8mg in the US – an important milestone in its ongoing work to help combat the opioid overdose epidemic.

FTSE 100 Trades Steady in Early Trade, European Stocks Fall

2023-10-03
The FTSE 100 traded steady in early trade while European stocks fell as concerns about rising bond yields return to weigh on sentiment and positive news over the weekend on the U.S. avoiding a government shutdown faded.

Hikma downgraded to Sector Perform from Outperform at RBC Capital

2023-09-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Marks & Spencer Makes a Return to the FTSE 100 as Hiscox Loses Out in Reshuffle

2023-08-30
(Bloomberg) -- Hiscox Ltd.’s short-lived stint in the FTSE 100 Index is coming to an end.Most Read from BloombergSingapore S$1 Billion Laundering Scandal Embroils Its Banking GiantsS&P 500 Tops 4,500 as Data Fuel Fed Peak Debate: Markets WrapCitadel Vets 69,000 Intern Applicants to Find Next Math GeniusesPutin Agrees to Visit China in First Trip Since Arrest WarrantWhat to Do With a 45-Story Skyscraper and No TenantsThe insurer has slipped a place in the rankings since being spared in last week’